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OBJECTIVEdGlutamine reduces postprandial glycemia when given before oral glucose. We
evaluated whether this is mediated by stimulation of insulin and/or slowing of gastric emptying.
RESEARCH DESIGN AND METHODSdTen healthy subjects were studied during
intraduodenal (ID) infusion of glutamine (7.5 or 15 g) or saline over 30 min, followed by glucose
(75 g over 100 min), while recording antropyloroduodenal pressures. Ten patients with type 2
diabetes mellitus (T2DM) were also studied with 15 g glutamine or saline.
RESULTSdID glutamine stimulated glucagon-like peptide 1 (GLP-1; healthy: P , 0.05;
T2DM: P , 0.05), glucose-dependent insulinotropic polypeptide (GIP; P = 0.098; P , 0.05),
glucagon (P, 0.01; P, 0.001), insulin (P = 0.05; P, 0.01), and phasic pyloric pressures (P,
0.05; P , 0.05), but did not lower blood glucose (P = 0.077; P = 0.5).
CONCLUSIONSdGlutamine does not lower glycemia after ID glucose, despite stimulating
GLP-1, GIP, and insulin, probably due to increased glucagon. Its capacity for pyloric stimulation
suggests that delayed gastric emptying is a major mechanism for lowering glycemia when glu-
tamine is given before oral glucose.
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P ostprandial glycemic control re-presents a major focus of type 2diabetes mellitus (T2DM) manage-
ment (1). The rate of gastric emptying and
the release of “incretin”hormones, glucagon-
like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide
(GIP), are both important determinants
of postprandial glycemic excursions (2).
Glucose empties from the stomach in
health in the range of 1–4 kcal/min, reg-
ulated by inhibitory small-intestinal
feedback via stimulation of pyloric motil-
ity and suppression of antral and duode-
nal contractions (3). Differences in gastric
emptying account for about one-third of
the variation in postprandial blood glu-
cose levels after oral glucose (4).
Glutamine reduces glucose excursions
when given before oral glucose in T2DM
(5), potentially by stimulating GLP-1 secre-
tion (6) and/or slowing gastric emptying
(7). The purpose of the current study was
to determine whether glutamine retains its
capacity to lower glycemia when glucose is
delivered directly into the duodenum,
thereby removing any inﬂuence of gastric
emptying, while measuring antropyloro-




3.8 years, BMI 22.66 0.7 kg/m2) and 10
patients (5 men) with diet-controlled
T2DM (68 6 1.1 years, BMI 28.9 6 1.1
kg/m2, HbA1c 6.7 6 0.2% [49.7 6 1.5
mmol/mol]) gave written, informed con-
sent. The protocol was approved by the
Royal Adelaide Hospital Research Ethics
Committee.
After an overnight fast, a multilumen
manometry catheter (Dentsleeve Interna-
tional, Mississauga, ON, Canada) was in-
serted transnasally and positioned with a
sleeve sensor across the pylorus. Healthy
subjects received an intraduodenal (ID)
infusion containing 15 or 7.5 g glutamine
in 350 mL aqueous solution, or 350 mL of
0.9% saline control, over 30 min (t = 0–30
min) in randomized, single-blinded order.
Thiswas followed by an IDglucose infusion
at 3 kcal/min over 100 min (t = 30–130
min) with frequent blood sampling. Pa-
tients with T2DM were studied only twice
(15 g glutamine or saline).
Blood glucose was analyzed using a
Medisense Precision glucometer (Abbott
Laboratories, Bedford, MA), and serum
insulin, total GLP-1 and GIP, and glucagon
were measured using established assays
(8). Manometric pressures were analyzed
using custom-designed software (9) to
count isolated pyloric pressure waves
(IPPWs) and the total number of waves in
all antral and duodenal channels, respec-
tively.
Data were analyzed over two periodsd
glutamine/saline infusion (t = 0–30 min)
and glucose infusion (t = 30–130 min). In-
cremental areas under the curves (iAUC)
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Figure 1dEffects of ID saline (control) and 7.5 or 15 g glutamine infusions on blood glucose (A and B), plasma GLP-1 (C and D), plasma GIP
(E and F), serum insulin (G andH), and plasma glucagon (I and J) concentrations in 10 healthy subjects and 9 patients with T2DM, before (t = 0–30
min) and during (t = 30–130 min) ID glucose infusion. *P = 0.05 for greater iAUC for 15 vs. 7.5 g glutamine or saline (127.16 33.1 vs. 45.16 12.7
vs. 51.46 23.1 pmol/L/min), **P, 0.05 for greater iAUC for 15 vs. 7.5 g glutamine (1,7156 440 vs. 1,0996 354 pmol/L/min), a P, 0.05 for
greater iAUC for 15 g glutamine vs. saline (84.6 6 19.3 vs. 37.0 6 27.1 pmol/L/min), r P, 0.05 for greater iAUC for 15 g glutamine vs. saline
(110.36 36.6 vs. 10.86 7.0 pmol/L/min), « P = 0.05 for greater iAUC for 15 vs. 7.5 g glutamine or saline (32.36 9.4 vs. 20.16 8.4 vs. 8.36 3.9
mU/L/min), d P, 0.01 for greater iAUC for 15 g glutamine vs. saline (62.86 19.9 vs. 5.76 3.4 mU/L/min), dd P, 0.05 for greater iAUC for 15 g
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were compared using one-factor ANOVA
for healthy subjects and paired t tests for
patients with T2DM. Post hoc compari-
sons, adjusted for multiple comparisons
by Bonferroni’s correction, were performed
if ANOVAs revealed signiﬁcant effects. Cal-
culations were done with SPSS 19 software
(IBM Corporation, Armonk, NY). Data are
means6 SE. Statistical signiﬁcance was ac-
cepted at P , 0.05.
RESULTSdThe study was well toler-
ated; one patient with T2DMwas excluded
due to marked nausea with glutamine.
Blood glucose was unchanged during
ID glutamine/saline infusion. The in-
crease in blood glucose during ID glucose
infusion did not differ between treat-
ments in health or T2DM (Fig. 1A and B).
Plasma GLP-1 increased during ID
glutamine infusion in health (P = 0.05)
and T2DM (P, 0.05). During ID glucose
infusion, GLP-1 concentrations in health
increased more after 15 g glutamine than
7.5 g glutamine or saline (P , 0.05),
whereas in T2DM, the increment was
nonsigniﬁcantly greater after 15 g gluta-
mine (P = 0.056; Fig. 1C and D).
Plasma GIP increased during ID glu-
tamine infusion in T2DM (P, 0.05), but
not signiﬁcantly in health (P = 0.098).
During ID glucose infusion, GIP concen-
trations increased similarly with all treat-
ments in both groups (Fig. 1E and F).
Serum insulin increased slightly during
ID glutamine infusion in health (P = 0.05)
and T2DM (P , 0.01). During ID glucose
infusion, insulin concentrations increased
without any difference between treatments
in health, whereas in T2DM, the increment
in insulin was greater after glutamine than
after saline (P , 0.05; Fig. 1G and H).
Plasma glucagon increased during ID
glutamine infusion in health, with a greater
increment for 15 g than for 7.5 g glutamine
(P , 0.005), and also increased in T2DM
(P , 0.005). During ID glucose infusion,
glucagon concentrations in health were
greater after 15 and7.5 g glutamine than after
saline (P, 0.01) and were greater after glu-
tamine in T2DM (P, 0.001; Fig. 1I and J).
Antropyloroduodenal pressures
There were more IPPWs during 15 g
glutamine infusion than 7.5 g glutamine
or saline in health (19.5 6 6.7 vs. 7.9 6
3.6 vs. 3.6 6 1.6, P , 0.05), and more
IPPWs during glutamine than saline in
T2DM (16.1 6 5.1 vs. 5.5 6 1.8, P ,
0.05). During ID glucose infusion, the
number of IPPWs did not differ between
treatments in either group (healthy:
28.4 6 8.7 vs. 24.5 6 8.7 vs. 24.5 6
8.2; T2DM: 57.9 6 9.4 vs. 60.56 14.7).
The number of antral waves did not
differ between treatments during ID glu-
tamine/saline infusion in health (26.5 6
10.7 vs. 30.5 6 7.7 vs. 44.3 6 15.1),
but antral waves were fewer in T2DM af-
ter glutamine compared with saline
(10.6 6 5.6 vs. 32.9 6 10.3, P , 0.05).
During ID glucose infusion, the number
of antral waves did not differ between
treatments in either group (healthy:
18.9 6 15.2 vs. 20.2 6 12.9 vs. 22.9 6
8.7; T2DM: 10.5 6 2.3 vs. 14.3 6 9.2).
The number of duodenal waves did
not differ between treatments during ID
glutamine/saline (healthy: 289.7 6 50.4
vs. 376.6 6 43.8 vs. 295.4 6 62.0;
T2DM: 215.3 6 63.2 vs. 213.9 6 39.6)
or ID glucose infusion (healthy: 160.5 6
72.6 vs. 156.4 6 64.1 vs. 128.3 6 33.8;
T2DM: 75.1 6 24.7 vs. 84.9 6 32.9) in
either group.
CONCLUSIONSdWe demonstrated
that 15 g ID glutamine stimulated GLP-1
secretion in health and T2DM, associated
with modest insulin stimulation. How-
ever the glycemic response to a subse-
quent ID glucose load was not
diminished, probably because of in-
creased glucagon. Glutamine stimulated
pyloric motility, which would delay gas-
tric emptying. The effects of glutamine on
hormone secretion and motility appeared
to be dose-dependent, because the effects
of 7.5 g glutamine were no different from
saline.
We infused glutamine over 30 min
based on the timing of themaximal GLP-1
response to oral glutamine (6). A higher
dosemight have had greater effects, but in
pilot studies, 30 g infused over 30 min
tended to induce nausea. Despite rela-
tively few subjects, the effects were con-
sistent, and it is unlikely that studying
more subjects would alter the outcomes
substantially. An additional day giving
glucose orally would be of interest, as
would an evaluation of other amino acids
and inclusion of patients with less well
controlled diabetes. Nevertheless, slow-
ing of gastric emptying appears the pre-
dominant mechanism by which glutamine
can lower glycemia.
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